A Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Agilent Technologies closed out fiscal 2025 on a strong note, posting Q4 revenue of $1.86 billion, up 9.4% year-over-year and ahead of the $1.83 billion consensus estimate, while non-GAAP EPS of $1.59 edged past the $1.58 Wall Street forecast. The re… Read more Agilent Technologies closed out fiscal 2025 on a strong note, posting Q4 revenue of $1.86 billion, up 9.4% year-over-year and ahead of the $1.83 billion consensus estimate, while non-GAAP EPS of $1.59 edged past the $1.58 Wall Street forecast. The results reflected broad-based momentum across all three business segments, with the Life Sciences and Diagnostics Markets Group leading the charge at 15% reported revenue growth, underscoring a recovery in demand that had weighed on the company in prior periods. The Agilent CrossLab Group remained the largest contributor for the full fiscal year at $2.91 billion in revenue with a 32.5% operating margin, lending the business a recurring revenue stability that analysts have noted as a key valuation anchor, much as investors in other diagnostics and life science names have rewarded consistent earnings execution. Looking ahead, Agilent guided FY2026 revenue to $7.30 billion to $7.40 billion with non-GAAP EPS of $5.86 to $6.00, signaling continued confidence in its growth trajectory.